CX Institutional’s GSK GSK Stock Holding History

CX Institutional’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$43K	Buy	883 +1	+0.1%	+$51	﹤0.01%	1044
2026 Q2	$46K	Buy	882 +100	+13%	+$5.29K	﹤0.01%	996
2026 Q1	$43K	Sell	782 -15	-2%	-$813	﹤0.01%	997
2025 Q4	$39K	Buy	797 +21	+3%	+$979	﹤0.01%	1009
2025 Q3	$33K	Sell	776 -1,217	-61%	-$47.5K	﹤0.01%	1010
2025 Q2	$77K	Buy	1,993 +818	+70%	+$31.3K	﹤0.01%	799
2025 Q1	$46K	Buy	+1,175	New	+$43K	﹤0.01%	845
2022 Q3	–	Sell	-582	Closed	-$32K	–	747
2022 Q2	$32K	Buy	+582	New	+$32.1K	﹤0.01%	759
2020 Q2	–	Sell	-42	Closed	-$2K	–	859
2020 Q1	$2K	Buy	+42	New	+$2.24K	﹤0.01%	670
2019 Q2	–	Sell	-1,334	Closed	-$70K	–	967
2019 Q1	$70K	Buy	+1,334	New	+$66.7K	0.01%	305

Other funds holding GSK

KFP

Keystone Financial Planning Cleveland, Ohio $404M AUM 16.77% 1-Year Est. Return

Bonness Enterprises Washington, District of Columbia $307M AUM 22.88% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Parrish Capital Kennesaw, Georgia $103M AUM 35.11% 1-Year Est. Return

IRC

Investors Research Corp Atlanta, Georgia $569M AUM 15.41% 1-Year Est. Return

BCM

Boltwood Capital Management Walnut Creek, California $443M AUM 17.72% 1-Year Est. Return

VCM

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

CPBTD

Central Pacific Bank - Trust Division Honolulu, Hawaii $952M AUM 25.15% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Rockland Trust Hanover, Massachusetts $2.61B AUM 14.26% 1-Year Est. Return

CX Institutional's GSK Position: Q3 2026 in Review

CX Institutional increased its GSK (GSK) stake by 0.11% in Q3 2026, buying an estimated $51 and bringing the position to 883 shares worth $43K. The position accounts for ﹤0.01% of the portfolio, ranked #1044.

CX Institutional first reported a position in GSK in Q1 2019 and has held it in 10 quarters since. The position peaked at $77K in Q2 2025. 31 funds tracked by Wall St. Rank hold GSK as of Q3 2026.

CX Institutional held 883 shares of GSK worth $43K as of Q3 2026.
CX Institutional bought 1 GSK share in Q3 2026, an estimated $51.
GSK made up ﹤0.01% of CX Institutional's portfolio in Q3 2026, its #1044 holding.
CX Institutional first reported a position in GSK in Q1 2019 and has held it in 10 quarters since.
CX Institutional's GSK position peaked at $77K in Q2 2025.
31 funds tracked by Wall St. Rank held GSK as of Q3 2026.

Based on CX Institutional's 13F filing for Q3 2026, filed 2 Oct 2026.